A Clinical and Imaging Registry of Transcatheter Aortic Valve Implantation Using JenaValve System/ J-Valve System for Patients With Pure Aortic Regurgitation
A Clinical and Imaging Registry of Transcatheter Aortic Valve Implantation Using JenaValve System/ J-Valve System for Patients With Pure Aortic Regurgitation: An Observational Study
Prince of Wales Hospital, Shatin, Hong Kong
30 participants
Apr 1, 2025
OBSERVATIONAL
Conditions
Summary
Aortic regurgitation (AR) is not uncommon. Transcatheter aortic valve implantation (TAVI) for treating pure aortic regurgitation is a potential future treatment option for pure AR especially in patients having high risk for open heart surgery. TAVI using dedicated device for pure AR has a different anchor mechanism to TAVI for aortic stenosis (AS). AR patientsalso have different cardiac flow pattern, aortic root pathology and left ventricular remodeling pattern compared to AS patients. Subclinical leaflet thrombosis has been described in AS patient receiving TAVI, which will affect the durability and antithrombotic regime. Follow-up imaging for dedicated TAVI device in AR patient is limited.
Eligibility
Inclusion Criteria4
- receiving transcatheter aortic valve implantation (TAVI) (using Jenavalve/J-Valve) in PWH
- with severe symptomatic AR (NYHA III-IV) despite optimal medical therapy
- Deemed high risk for aortic valve surgery determined by a multidisciplinary heart team (including cardiologists, cardiac surgeons and cardiac anesthetists)
- Capable of providing informed consent
Exclusion Criteria7
- Evidence of intracardiac mass, thrombus or vegetation
- Anatomical structures precluding proper device deployment or device vascular access, evaluated by echo or CT
- Sepsis or active endocarditis within 3 months, or infections requiring antibiotic therapy within 2 weeks prior to the planned procedure
- Subjects currently participating in another clinical trial of an investigational drug or device that has not yet completed its primary endpoint.
- Chronic Kidney Disease with eGFR <30 ml/min/1.73m2.
- Cardiogenic shock or other hemodynamic instability requiring inotropic support or ventricular assist device
- Contraindicated for CT or MRI assessment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
JenaValve is a newly developed advanced TAVI system developed by Jenavalve Technology Inc.
J-Valve is a newly developed advanced TAVI system developed by Genesis Medtech.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07021612